RIPK3 and neoplasm: Importantly, inhibition of NF-κΒ activation via BAY-117085, significantly reduced both the tumor control effects and the survival advantage, demonstrating that intact NF-κΒ transcriptional signaling downstream of RIPK1/RIPK3 activation is required for the immunogenicity of necroptotic cells in the TME (Fig. 5).